U.S., Aug. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07132333) titled 'Molecular Inflammation Board at the Center for Personalized Medicine' on Aug. 11.
Brief Summary: Molecular Inflammation Board at the Center for Personalized Medicine
Study Start Date: Nov. 16, 2022
Study Type: OBSERVATIONAL
Condition:
Psoriasis (PsO)
Psoriasis Arthritis
Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis)
Spondylarthropathies
Intervention:
BIOLOGICAL: Biologic Agent
Intervention with biologic agents
Recruitment Status: RECRUITING
Sponsor: University Hospital Tuebingen
Published by HT Digital Content Services with permission from Health Daily Digest....